Protocols
ADICET-ADI-001-BCELL Phase I OPEN TO ACCRUAL
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
ALLOGENE-ALLO-501A-201 Phase I OPEN TO ACCRUAL
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-501A and Anti-CD19 Allogeneic CAR-T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
IIT-SHAH-IL7-IL15-CD20-19 Phase I/II OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies